Literature DB >> 17188619

Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome.

Elif Seda Selamet Tierney1, Brian Feingold, Beth F Printz, Sang C Park, Dionne Graham, Charles S Kleinman, C Becket Mahnke, Donna M Timchak, William H Neches, Welton M Gersony.   

Abstract

OBJECTIVE: To test the hypothesis that chronic beta-blocker therapy in pediatric patients with Marfan syndrome alters the rate of aortic root dilation. Beta-blockade has been advocated as preventive therapy for Marfan syndrome based on reports indicating a decreased rate of aortic root dilation in treated patients. STUDY
DESIGN: Patients with Marfan syndrome (n = 63) followed at Children's Hospital of Pittsburgh or Children's Hospital of New York-Presbyterian who had > or =18 months of echocardiographic follow-up were studied. All clinical data and 213 serial echocardiograms were reviewed, and aortic root dimensions were measured. Patients were divided into 2 groups for comparison: untreated (n = 34) and treated (n = 29).
RESULTS: At study entry, the 2 study groups were comparable in terms of age, sex, body surface area (BSA), aortic root measurements, heart rate, and corresponding z scores. Follow-up duration in each group was similar. At last follow-up, heart rates and heart rate z scores were lower in the treated group. Rates of change of aortic root measurements (P = .52) and the corresponding z scores were not statistically different between the 2 group at the study's end.
CONCLUSIONS: This study suggests that that beta-blocker therapy does not significantly alter the rate of aortic root dilation in children with Marfan syndrome. Based on these data, the recommendation of lifetime beta-blocker therapy instituted during childhood should be reassessed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17188619     DOI: 10.1016/j.jpeds.2006.09.003

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  20 in total

Review 1.  Aortic Involvement in Pediatric Marfan syndrome: A Review.

Authors:  Omonigho Ekhomu; Zahra J Naheed
Journal:  Pediatr Cardiol       Date:  2015-02-11       Impact factor: 1.655

2.  Report of the National Heart, Lung, and Blood Institute and National Marfan Foundation Working Group on research in Marfan syndrome and related disorders.

Authors:  Gail D Pearson; Richard Devereux; Bart Loeys; Cheryl Maslen; Dianna Milewicz; Reed Pyeritz; Francesco Ramirez; Daniel Rifkin; Lynn Sakai; Lars Svensson; Andy Wessels; Jennifer Van Eyk; Harry C Dietz
Journal:  Circulation       Date:  2008-08-12       Impact factor: 29.690

Review 3.  Marfan syndrome. Part 2: treatment and management of patients.

Authors:  Victoria Cañadas; Isidre Vilacosta; Isidoro Bruna; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2010-03-30       Impact factor: 32.419

4.  Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy.

Authors:  Ronald V Lacro; Lin T Guey; Harry C Dietz; Gail D Pearson; Anji T Yetman; Bruce D Gelb; Bart L Loeys; D Woodrow Benson; Timothy J Bradley; Julie De Backer; Geoffrey A Forbus; Gloria L Klein; Wyman W Lai; Jami C Levine; Mark B Lewin; Larry W Markham; Stephen M Paridon; Mary Ella Pierpont; Elizabeth Radojewski; Elif Seda Selamet Tierney; Angela M Sharkey; Stephanie Burns Wechsler; Lynn Mahony
Journal:  Am Heart J       Date:  2013-03-26       Impact factor: 4.749

5.  Medical management of aortic disease in Marfan syndrome.

Authors:  Syed Usman Bin Mahmood; Camilo A Velasquez; Mohammad A Zafar; Ayman A Saeyeldin; Adam J Brownstein; Bulat A Ziganshin; John A Elefteriades; Sandip K Mukherjee
Journal:  Ann Cardiothorac Surg       Date:  2017-11

Review 6.  Therapies for Thoracic Aortic Aneurysms and Acute Aortic Dissections.

Authors:  Dianna M Milewicz; Francesco Ramirez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-02       Impact factor: 8.311

7.  MMP-2 regulates Erk1/2 phosphorylation and aortic dilatation in Marfan syndrome.

Authors:  Wanfen Xiong; Trevor Meisinger; Rebecca Knispel; Jennifer M Worth; B Timothy Baxter
Journal:  Circ Res       Date:  2012-05-01       Impact factor: 17.367

Review 8.  Echocardiographic methods, quality review, and measurement accuracy in a randomized multicenter clinical trial of Marfan syndrome.

Authors:  Elif Seda Selamet Tierney; Jami C Levine; Shan Chen; Timothy J Bradley; Gail D Pearson; Steven D Colan; Lynn A Sleeper; M Jay Campbell; Meryl S Cohen; Julie De Backer; Lin T Guey; Haleh Heydarian; Wyman W Lai; Mark B Lewin; Edward Marcus; Christopher R Mart; Ricardo H Pignatelli; Beth F Printz; Angela M Sharkey; Girish S Shirali; Shubhika Srivastava; Ronald V Lacro
Journal:  J Am Soc Echocardiogr       Date:  2013-04-10       Impact factor: 5.251

9.  Role of beta-blockers in Marfan's syndrome and bicuspid aortic valve: A time for re-appraisal.

Authors:  Balu Vaidyanathan
Journal:  Ann Pediatr Cardiol       Date:  2008-07

10.  Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.

Authors:  Ronald V Lacro; Harry C Dietz; Lisa M Wruck; Timothy J Bradley; Steven D Colan; Richard B Devereux; Gloria L Klein; Jennifer S Li; L LuAnn Minich; Stephen M Paridon; Gail D Pearson; Beth F Printz; Reed E Pyeritz; Elizabeth Radojewski; Mary J Roman; J Philip Saul; Mario P Stylianou; Lynn Mahony
Journal:  Am Heart J       Date:  2007-10       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.